Apple Awards $10 Million to COPAN Diagnostics to Accelerate Supply of COVID-19 Sample Collection Kits
Posted May 7, 2020 at 6:28pm by iClarified
Apple has award $10 million from its Advanced Manufacturing Fund to COPAN Diagnostics, a company that supplies sample collection kits for COVID-19 testing.
This funding will allow COPAN Diagnostics to rapidly accelerate their supply of sample collection kits for hospitals across the United States, expanding production from several thousand today to more than one million kits per week by early July. As part of this effort, Apple will support COPAN Diagnostics’ expansion to a new, larger facility in Southern California, with advanced equipment that Apple is helping design. This expansion is expected to create more than 50 new jobs.
“We feel a deep sense of responsibility to do everything we can to help medical workers, patients, and communities support the global response to COVID-19,” said Jeff Williams, Apple’s chief operating officer. “COPAN is one of the world’s most innovative manufacturers of sample collection kits for COVID-19 testing, and we’re thrilled to partner with them so they can expand as we work to address this critical issue for our nation. I couldn’t be prouder of our teams for bringing all of their energy, passion, and innovative spirit to supporting the country’s COVID-19 response.”
“We’re excited to forge this new relationship with Apple, whose teams are already making a huge difference with our efforts to scale up the production of our sample collection and transport kits,” said Norman Sharples, CEO of COPAN Diagnostics. “Collection and transport kits are a critical component in the fight against COVID-19. At COPAN, we’re excited and grateful for this partnership with Apple as our strong beliefs of innovation, quality, and excellence in manufacturing and design are perfectly aligned. Apple’s operational expertise will help us increase delivery of important pre-analytical tools for medical professionals across the country at this critical time.”
COPAN is a global player in the field of specimen collection and preservation for infectious disease diagnostics. The company’s sample collection kits have revolutionized the diagnostic industry and play a critical role in the COVID-19 testing process. The company’s unique quantitative approach to pre-analytics led them to invent flocked swabs in 2003, a revolutionary device comprising of a molded plastic applicator stick that has variable tips coated with Nylon fibers allowing for quick uptake and complete elution of the sample. COPAN’s UTM is the leading transport medium for collection, transport, preservation, and long-term freeze storage of clinical specimens containing viruses.
Apple is sourcing equipment and materials for COPAN Diagnostics from companies across the US. This includes equipment Apple is helping design from K2 Kinetics, based in York, Pennsylvania, and MWES in Waukesha, Wisconsin.
Please download the iClarified app or follow iClarified on Twitter, Facebook, YouTube, and RSS for updates.
This funding will allow COPAN Diagnostics to rapidly accelerate their supply of sample collection kits for hospitals across the United States, expanding production from several thousand today to more than one million kits per week by early July. As part of this effort, Apple will support COPAN Diagnostics’ expansion to a new, larger facility in Southern California, with advanced equipment that Apple is helping design. This expansion is expected to create more than 50 new jobs.
“We feel a deep sense of responsibility to do everything we can to help medical workers, patients, and communities support the global response to COVID-19,” said Jeff Williams, Apple’s chief operating officer. “COPAN is one of the world’s most innovative manufacturers of sample collection kits for COVID-19 testing, and we’re thrilled to partner with them so they can expand as we work to address this critical issue for our nation. I couldn’t be prouder of our teams for bringing all of their energy, passion, and innovative spirit to supporting the country’s COVID-19 response.”
“We’re excited to forge this new relationship with Apple, whose teams are already making a huge difference with our efforts to scale up the production of our sample collection and transport kits,” said Norman Sharples, CEO of COPAN Diagnostics. “Collection and transport kits are a critical component in the fight against COVID-19. At COPAN, we’re excited and grateful for this partnership with Apple as our strong beliefs of innovation, quality, and excellence in manufacturing and design are perfectly aligned. Apple’s operational expertise will help us increase delivery of important pre-analytical tools for medical professionals across the country at this critical time.”
COPAN is a global player in the field of specimen collection and preservation for infectious disease diagnostics. The company’s sample collection kits have revolutionized the diagnostic industry and play a critical role in the COVID-19 testing process. The company’s unique quantitative approach to pre-analytics led them to invent flocked swabs in 2003, a revolutionary device comprising of a molded plastic applicator stick that has variable tips coated with Nylon fibers allowing for quick uptake and complete elution of the sample. COPAN’s UTM is the leading transport medium for collection, transport, preservation, and long-term freeze storage of clinical specimens containing viruses.
Apple is sourcing equipment and materials for COPAN Diagnostics from companies across the US. This includes equipment Apple is helping design from K2 Kinetics, based in York, Pennsylvania, and MWES in Waukesha, Wisconsin.
Please download the iClarified app or follow iClarified on Twitter, Facebook, YouTube, and RSS for updates.